ES2314362T3 - Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas. - Google Patents

Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas. Download PDF

Info

Publication number
ES2314362T3
ES2314362T3 ES04702584T ES04702584T ES2314362T3 ES 2314362 T3 ES2314362 T3 ES 2314362T3 ES 04702584 T ES04702584 T ES 04702584T ES 04702584 T ES04702584 T ES 04702584T ES 2314362 T3 ES2314362 T3 ES 2314362T3
Authority
ES
Spain
Prior art keywords
compound
formula
receptor
agent
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04702584T
Other languages
English (en)
Spanish (es)
Inventor
David M. Weiner
Robert E. Davis
Mark R. Brann
Norman Nash
Carl - Magnus A. Andersson
Allan K. Uldam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acadia Pharmaceuticals Inc
Original Assignee
Acadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32776052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2314362(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acadia Pharmaceuticals Inc filed Critical Acadia Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2314362T3 publication Critical patent/ES2314362T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES04702584T 2003-01-16 2004-01-15 Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas. Expired - Lifetime ES2314362T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44140603P 2003-01-16 2003-01-16
US441406P 2003-01-16
US47934603P 2003-06-17 2003-06-17
US479346P 2003-06-17

Publications (1)

Publication Number Publication Date
ES2314362T3 true ES2314362T3 (es) 2009-03-16

Family

ID=32776052

Family Applications (2)

Application Number Title Priority Date Filing Date
ES04702584T Expired - Lifetime ES2314362T3 (es) 2003-01-16 2004-01-15 Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas.
ES08015449T Expired - Lifetime ES2367135T3 (es) 2003-01-16 2004-01-15 Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilzados como agentes terapéuticos para enfermedades neurodegenerativas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES08015449T Expired - Lifetime ES2367135T3 (es) 2003-01-16 2004-01-15 Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilzados como agentes terapéuticos para enfermedades neurodegenerativas.

Country Status (21)

Country Link
US (17) US7601740B2 (de)
EP (2) EP1587789B1 (de)
JP (2) JP5184777B2 (de)
KR (1) KR101095939B1 (de)
CN (3) CN1816524B (de)
AT (2) ATE407117T1 (de)
AU (1) AU2004206886B2 (de)
BR (1) BRPI0406591B8 (de)
CA (1) CA2512639C (de)
CY (1) CY1108642T1 (de)
DE (1) DE602004016288D1 (de)
DK (2) DK1587789T3 (de)
ES (2) ES2314362T3 (de)
MX (1) MXPA05007568A (de)
NZ (1) NZ541146A (de)
PT (1) PT1587789E (de)
RU (2) RU2332401C2 (de)
SG (1) SG170617A1 (de)
SI (2) SI1587789T1 (de)
WO (1) WO2004064738A2 (de)
ZA (1) ZA200505680B (de)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100879647B1 (ko) * 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
NZ533567A (en) 2001-12-28 2007-06-29 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
JP2005533813A (ja) 2002-06-24 2005-11-10 アカディア ファーマシューティカルズ，インコーポレーテッド セロトニン受容体作用物質としてのｎ−置換ピペリジン誘導体
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) * 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
MY139563A (en) * 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
ATE407117T1 (de) 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
WO2004064753A2 (en) * 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US8304431B2 (en) * 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
BRPI0417749A (pt) 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
CN101031548B (zh) * 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
KR20060030175A (ko) * 2004-10-05 2006-04-10 경북대학교 산학협력단 무정위성 운동 치료용 약학조성물
MX2008012093A (es) * 2006-03-24 2008-10-03 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos.
US20080051429A1 (en) * 2006-04-19 2008-02-28 Van Kammen Daniel Use of 4-amino-piperidines for treating sleep disorders
CA2652300A1 (en) * 2006-05-15 2007-11-22 Acadia Pharmaceuticals Inc. Pharmaceutical formulations of pimavanserin
US20080040819A1 (en) * 2006-08-14 2008-02-14 Wyeth Methods of identifying agents for treatment of schizophrenia and related disorders
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US20100151459A1 (en) * 2007-01-26 2010-06-17 Jun Soo Kwon Marker for detecting the proposed efficacy of treatment
WO2008116024A2 (en) 2007-03-19 2008-09-25 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
EP2150239A1 (de) * 2007-04-24 2010-02-10 Boehringer Ingelheim International GmbH Kombination mit einer pramipexol oder ein pharmazeutisch annehmbares salz davon enthaltenden tablettenformulierung mit verlängerter freisetzung
GB2463833B (en) * 2007-06-26 2012-02-08 Parkinson S Inst Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders
NO2200610T3 (de) * 2007-09-21 2018-06-09
WO2009039461A2 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
TR201805216T4 (en) 2008-10-28 2018-06-21 Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
US9446037B2 (en) 2012-11-27 2016-09-20 Acadia Pharmaceuticals Inc. Methods for the treatment of parkinson's disease psychosis using pimavanserin
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
TWI690512B (zh) * 2014-03-07 2020-04-11 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途
CN104961671B (zh) * 2014-09-05 2018-01-02 苏州晶云药物科技有限公司 N‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑(2‑甲基丙氧基)‑苯基甲基)脲半酒石酸盐的晶型及其制备方法
ES2985064T3 (es) * 2015-01-28 2024-11-04 Univ Duke Composición que comprende metilfenidato y ondansetrón para su uso en trastornos relacionados con la toxicomanía
EP3271018B1 (de) 2015-03-02 2020-12-23 Pliva Hrvatska D.O.O. Verfahren und zwischenprodukte zur herstellung von pimavanserin
CN108472285A (zh) * 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
CN107848972B (zh) * 2015-07-20 2021-06-18 阿卡蒂亚药品公司 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法
CZ2015601A3 (cs) 2015-09-02 2017-03-15 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty
CZ2015688A3 (cs) 2015-10-02 2017-04-12 Zentiva, K.S. Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jeho deuterovaných analogů
CN105523993A (zh) * 2015-12-28 2016-04-27 重庆两江药物研发中心有限公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲酒石酸盐晶型c及制备应用
HUE061547T2 (hu) 2016-03-22 2023-07-28 Helsinn Healthcare Sa Aszimmetrikus benzolszulfonil-karbamid-származékok és gyógyászati alkalmazásuk
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
EP3436010B1 (de) 2016-03-29 2021-03-10 Acadia Pharmaceuticals Inc. Inverse 5-ht2a-serotonin-rezeptor-agonisten oder -antagonisten zur verwendung in der verringerung von amyloid-beta-peptiden und in der verringerung der akkumulation von amyloid-plaques
CN107343887A (zh) * 2016-05-06 2017-11-14 常州爱诺新睿医药技术有限公司 一种无定型半酒石酸匹莫范色林与药用辅料的固体分散体及其制备方法
CN106179449B (zh) * 2016-07-18 2018-11-13 南京工业大学 一种碳氮材料负载的钴催化剂及合成哌马色林中间体的方法
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
EP3519816A4 (de) 2016-09-29 2020-05-06 The Regents of the University of California Verbindungen zur erhöhung der neuronalen plastizität
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
EP3558311A1 (de) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin allein oder in kombination zur verwendung in der behandlung von morbus-alzheimer-psychose
EP3600325A4 (de) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. Neuartige zusammensetzungen und verfahren
WO2018200977A1 (en) 2017-04-28 2018-11-01 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
KR102608479B1 (ko) 2017-05-25 2023-12-01 글리테크 엘엘씨. Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
CA3067162A1 (en) 2017-06-12 2018-12-20 Glytech Llc. Composition and method for treatment or depression and psychosis in humans
CN109111385B (zh) * 2017-06-23 2023-06-30 上海翰森生物医药科技有限公司 5-ht2a受体抑制剂及其制备方法和应用
US11440884B2 (en) 2017-08-21 2022-09-13 Acadia Pharmaceuticals Inc. Compounds, salts thereof and methods for treatment of diseases
WO2019040107A1 (en) 2017-08-21 2019-02-28 Acadia Pharmaceuticals Inc. COMPOUNDS, CORRESPONDING SALTS AND METHODS FOR THE TREATMENT OF DISEASES
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
CN109568278A (zh) * 2017-09-28 2019-04-05 北京万全德众医药生物技术有限公司 匹莫范色林片剂及其制备方法
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11357766B2 (en) * 2017-11-13 2022-06-14 Texas Tech University System Compositions and methods for treating cancer
KR102036909B1 (ko) * 2017-11-28 2019-10-25 한국과학기술원 신규 디스토니아 치료용 약학적 조성물
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
IT201800003736A1 (it) 2018-03-19 2019-09-19 Lundbeck Pharmaceuticals Italy S P A Processo per la produzione di Pimavanserin
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
US20190359985A1 (en) * 2018-05-22 2019-11-28 John Lawrence Mee Adjustable method for sustainable human cognitive enhancement
CN108947891B (zh) 2018-07-26 2021-02-09 丽珠集团新北江制药股份有限公司 利用三光气安全制备匹莫范色林及其酒石酸盐的方法
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
IT201800009690A1 (it) 2018-10-23 2020-04-23 Lundbeck Pharmaceuticals Italy Spa Processo per la produzione di pimavanserina
WO2020176597A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
EP4134101A1 (de) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuteriertes lumateperon zur behandlung der bipolar-ii-störung
WO2021016369A1 (en) 2019-07-22 2021-01-28 Acadia Pharmaceuticals Inc. Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder
US20220323429A1 (en) * 2019-08-15 2022-10-13 Acadia Pharmaceuticals Inc. Pimavanserin for treating neurodegenerative diseases
KR102227268B1 (ko) * 2019-10-07 2021-03-12 한국과학기술원 디스토니아 치료 후보 약물의 신규 스크리닝 방법
CN115677723B (zh) * 2020-01-21 2024-06-04 瀚远医药有限公司 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
WO2021147818A1 (zh) * 2020-01-21 2021-07-29 瀚远医药有限公司 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
CN113214141B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其制备和应用
CN115605202B (zh) 2020-03-26 2025-10-28 盐野义制药株式会社 具有血清素受体结合活性的芳香族杂环衍生物
WO2021206741A1 (en) * 2020-04-09 2021-10-14 Delahoussaye Kevin Modulating neurotransmitter concentration
CN114728933B (zh) * 2020-07-22 2023-06-16 山东绿叶制药有限公司 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
WO2022098106A1 (ko) * 2020-11-04 2022-05-12 주식회사 오에이티씨 클로르프로마진을 포함하는 신경 염증성 질환의 예방 또는 치료용 조성물
WO2022145408A1 (ja) 2020-12-28 2022-07-07 塩野義製薬株式会社 セロトニン受容体結合活性を有する環状アミン誘導体
WO2022221415A2 (en) 2021-04-13 2022-10-20 The Regents Of The University Of California Tetracyclic compounds for treating brain disorders
CN113292484B (zh) * 2021-06-04 2022-11-15 沈阳药科大学 3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス，インク． フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
CN121318920A (zh) * 2022-08-03 2026-01-13 绿叶嘉奥制药石家庄有限公司 5-ht2a受体反向激动剂及其制备方法和应用
JP7406285B1 (ja) 2023-03-09 2023-12-27 国立大学法人島根大学 ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンｕｄｐ－グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物
WO2025162237A1 (zh) * 2024-02-02 2025-08-07 绿叶嘉奥制药石家庄有限公司 一种5-ht2a受体反向激动剂的盐型、晶型及其制备方法和应用

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US165225A (en) * 1875-07-06 Improvement in hubs
CA684843A (en) 1964-04-21 P. Roberts Cecil Cap aligning mechanism
BE794333A (fr) 1972-01-20 1973-07-19 Wyeth John & Brother Ltd Composes heterocycliques azotes therapeutiques
GB1507462A (en) 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
JPS5152176A (de) 1974-10-12 1976-05-08 Yoshitomi Pharmaceutical
JPS528517A (en) 1975-07-09 1977-01-22 Toyo Autom Kk Fluid line automatic closing system at an earthquake
GB1586468A (en) 1976-10-29 1981-03-18 Anphar Sa Piperidine derivatives
CA1140119A (en) 1978-04-03 1983-01-25 Joseph Torremans N-heterocyclyl-4-piperidinamines
US4255432A (en) 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
US4332804A (en) 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US4353901A (en) 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones
GB8527052D0 (en) 1985-11-02 1985-12-04 Beecham Group Plc Compounds
GB8621892D0 (en) 1986-09-11 1986-10-15 Lundbeck & Co As H Organic compound
FR2642069B1 (fr) 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
US5214055A (en) 1990-05-18 1993-05-25 Adir Et Compagnie Aminopiperidine 4-oxo-4H-chromen-2-yl compounds
US5216165A (en) 1990-10-03 1993-06-01 American Home Products Corporation N-substituted aminoquinolines as analgesic agents
IT1252227B (it) 1991-12-17 1995-06-05 Ciba Geigy Spa Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici
JPH05208517A (ja) 1992-01-31 1993-08-20 Nec Corp 印字制御回路
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
CA2123728A1 (en) 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1994027967A1 (en) 1993-05-26 1994-12-08 Smithkline Beecham Laboratoires Pharmaceutiques Novel compounds
IL110298A (en) 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
DE4404183A1 (de) 1994-02-10 1995-08-17 Merck Patent Gmbh 4-Amino-1-piperidylbenzoylguanidine
US5795894A (en) 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
WO1997011940A1 (en) 1995-09-29 1997-04-03 Eli Lilly And Company Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
EP0944388A4 (de) 1996-04-03 2001-08-16 Merck & Co Inc Hemmern von farnesyl protein transferase
JP2002503207A (ja) 1996-04-17 2002-01-29 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害剤としてのＮ―（アミジノフェニル）―Ｎ’―（置換）―３Ｈ―２，４―ベンゾジアゼピン―３―オン誘導体
US5869488A (en) 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
WO1998007431A1 (en) * 1996-08-22 1998-02-26 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
DE59711622D1 (de) 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE19643331A1 (de) 1996-10-21 1998-04-23 Thomae Gmbh Dr K 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
SE9604786D0 (sv) * 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
TR199902752T2 (xx) 1997-05-08 2000-06-21 Smithkline Beecham Corporation Proteaz inhibit�rleri.
GB9718833D0 (en) 1997-09-04 1997-11-12 Merck Sharp & Dohme Therapeutic agents
US6107324A (en) 1998-04-14 2000-08-22 Arena Pharmaceuticals Inc. 5-HT2A receptor inverse agonists
US6140509A (en) 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9816263D0 (en) 1998-07-24 1998-09-23 Merck Sharp & Dohme Therapeutic agents
US6358698B1 (en) * 1998-10-07 2002-03-19 Acadia Pharmacueticals Inc. Methods of identifying inverse agonists of the serotonin 2A receptor
CA2315050C (en) 1998-10-16 2009-02-03 Suntory Limited Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof
US6150393A (en) 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
EP1013276A1 (de) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkane als CCR5-Modulatoren
US6725038B1 (en) 1999-01-26 2004-04-20 Nokia Corporation Method and apparatus for speeding up AAL2 connection setup during handover in advanced cellular networks
CA2367112A1 (en) 1999-03-24 2000-09-28 The Regents Of The University Of California Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AU4537900A (en) 1999-05-17 2000-12-05 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US20050148018A1 (en) 1999-10-07 2005-07-07 David Weiner Methods of identifying inverse agonists of the serotonin 2A receptor
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
US7022698B2 (en) * 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6834122B2 (en) 2000-01-22 2004-12-21 Kairos Scientific, Inc. Visualization and processing of multidimensional data using prefiltering and sorting criteria
KR100879647B1 (ko) 2000-03-06 2009-01-20 아카디아 파마슈티칼스 인코포레이티드 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
DE60141752D1 (de) * 2000-06-30 2010-05-20 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
HUP0303360A2 (hu) 2000-09-25 2004-01-28 Actelion Pharmaceuticals Ltd. Maláriaellenes hatású szubsztituált amino-aza-cikloalkánok és ezeket tartalmazó gyógyszerkészítmények
US20020156068A1 (en) 2001-03-22 2002-10-24 Behan Dominic P. Anti-psychosis combination
GB0108099D0 (en) 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
NZ533567A (en) 2001-12-28 2007-06-29 Acadia Pharm Inc Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events
EP1509505A2 (de) 2002-01-23 2005-03-02 Arena Pharmaceuticals, Inc. Nicht-endogene, konstitutiv aktivierte rezeptoren für menschliches serotonin und modulatoren von kleiner molekülgrösse
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
GB0208279D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
JP2005533813A (ja) 2002-06-24 2005-11-10 アカディア ファーマシューティカルズ，インコーポレーテッド セロトニン受容体作用物質としてのｎ−置換ピペリジン誘導体
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2004039322A2 (en) 2002-10-29 2004-05-13 Miicro, Inc. Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
ATE407117T1 (de) * 2003-01-16 2008-09-15 Acadia Pharm Inc Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen
WO2004064753A2 (en) 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease
US8304431B2 (en) 2003-12-02 2012-11-06 Pharmaneuroboost N.V. Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
BRPI0417749A (pt) 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
CN101031548B (zh) 2004-09-27 2011-04-06 阿卡蒂亚药品公司 N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
JP4933450B2 (ja) 2005-01-10 2012-05-16 タヘリ ラドュカ エルエルシー インプラント可能装置を体内で展開するための機器および方法
CN101146763A (zh) 2005-03-30 2008-03-19 默克公司 胰高血糖素受体拮抗剂化合物、含有这种化合物的组合物以及使用方法
US8572080B2 (en) 2010-06-04 2013-10-29 Salesforce.Com, Inc. Methods and systems for analyzing a network feed in a multi-tenant database system environment
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9446037B2 (en) * 2012-11-27 2016-09-20 Acadia Pharmaceuticals Inc. Methods for the treatment of parkinson's disease psychosis using pimavanserin
US10953000B2 (en) * 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) * 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2019046167A1 (en) * 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS

Also Published As

Publication number Publication date
JP5184777B2 (ja) 2013-04-17
KR101095939B1 (ko) 2011-12-19
RU2005125918A (ru) 2006-02-10
AU2004206886A1 (en) 2004-08-05
US20140140982A1 (en) 2014-05-22
DE602004016288D1 (de) 2008-10-16
US8921393B2 (en) 2014-12-30
ES2367135T3 (es) 2011-10-28
US8008323B2 (en) 2011-08-30
PT1587789E (pt) 2008-12-16
US20060264465A1 (en) 2006-11-23
US20150202194A1 (en) 2015-07-23
US7659285B2 (en) 2010-02-09
CA2512639C (en) 2012-10-30
US9566271B2 (en) 2017-02-14
US20060264466A1 (en) 2006-11-23
US20100227885A1 (en) 2010-09-09
CA2512639A1 (en) 2004-08-05
NZ541146A (en) 2009-04-30
EP2009000B1 (de) 2011-06-08
US20100227886A1 (en) 2010-09-09
KR20050094857A (ko) 2005-09-28
US20170209424A1 (en) 2017-07-27
CY1108642T1 (el) 2014-04-09
ATE407117T1 (de) 2008-09-15
US20220241265A1 (en) 2022-08-04
DK1587789T3 (da) 2009-01-05
US20110257229A1 (en) 2011-10-20
CN1816524B (zh) 2012-06-27
US20040213816A1 (en) 2004-10-28
US10028944B2 (en) 2018-07-24
EP2009000A1 (de) 2008-12-31
BRPI0406591B8 (pt) 2021-05-25
WO2004064738A3 (en) 2004-11-25
US9211289B2 (en) 2015-12-15
RU2465267C2 (ru) 2012-10-27
HK1126776A1 (en) 2009-09-11
JP2010174026A (ja) 2010-08-12
CN1816524A (zh) 2006-08-09
WO2004064738A2 (en) 2004-08-05
US20130137727A1 (en) 2013-05-30
US20200323836A1 (en) 2020-10-15
MXPA05007568A (es) 2005-09-21
US20190030015A1 (en) 2019-01-31
US7713995B2 (en) 2010-05-11
CN101780080B (zh) 2014-06-04
SG170617A1 (en) 2011-05-30
ZA200505680B (en) 2006-04-26
SI2009000T1 (sl) 2011-09-30
BRPI0406591A (pt) 2005-12-20
US20160250200A1 (en) 2016-09-01
US7732462B2 (en) 2010-06-08
RU2332401C2 (ru) 2008-08-27
US7994193B2 (en) 2011-08-09
US20060199842A1 (en) 2006-09-07
US20240091212A1 (en) 2024-03-21
US10525046B2 (en) 2020-01-07
US20120277221A1 (en) 2012-11-01
US8227487B2 (en) 2012-07-24
US8618130B2 (en) 2013-12-31
JP2006516284A (ja) 2006-06-29
CN101780080A (zh) 2010-07-21
DK2009000T3 (da) 2011-09-05
CN102028949A (zh) 2011-04-27
US7601740B2 (en) 2009-10-13
HK1083759A1 (en) 2006-07-14
EP1587789A2 (de) 2005-10-26
ATE512136T1 (de) 2011-06-15
AU2004206886B2 (en) 2010-09-02
RU2008115009A (ru) 2009-10-27
EP1587789B1 (de) 2008-09-03
SI1587789T1 (sl) 2009-02-28
US8377959B2 (en) 2013-02-19
BRPI0406591B1 (pt) 2018-12-18

Similar Documents

Publication Publication Date Title
ES2367135T3 (es) Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilzados como agentes terapéuticos para enfermedades neurodegenerativas.
HK1126776B (en) Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
HK1083759B (en) Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases